MedTrace Logo

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

NCT04609579 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-01-30

No results posted yet for this study

Summary

This clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab (KEYTRUDA®) in participants with advanced solid tumors and lymphoma. The main goals of this study are to:

* Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab (KEYTRUDA®).
* Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®)
* Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®)
* Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®)

Conditions

  • Advanced Solid Tumor
  • Advanced Lymphoma

Interventions

DRUG

SNX281

SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.

DRUG

pembrolizumab

pembrolizumab (KEYTRUDA®) will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs.

Sponsors & Collaborators

Principal Investigators

  • Melissa Johnson, MD · SCRI Development Innovations, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-18
Primary Completion
2024-01-06
Completion
2024-01-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04609579 on ClinicalTrials.gov